- Home
- BMRN vs QGEN Comparison
BMRN vs QGEN Comparison
Compare BMRN & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | QGEN |
|---|---|---|
| Founded | 1996 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.2B |
| IPO Year | 1999 | 1998 |
Fundamental Metrics
Financial Performance| Metric | BMRN | QGEN |
|---|---|---|
| Price | $55.50 | $41.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $88.22 | $51.30 |
| AVG Volume (30 Days) | 1.8M | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $1,313,646,000.00 | N/A |
| Revenue This Year | $14.30 | $8.18 |
| Revenue Next Year | $11.65 | $5.66 |
| P/E Ratio | $30.84 | ★ $24.01 |
| Revenue Growth | ★ 17.62 | N/A |
| 52 Week Low | $50.76 | $38.58 |
| 52 Week High | $66.28 | $57.82 |
Technical Indicators
Market Signals| Indicator | BMRN | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 41.52 |
| Support Level | $54.67 | N/A |
| Resistance Level | $56.21 | $48.60 |
| Average True Range (ATR) | 1.54 | 0.88 |
| MACD | 0.07 | 0.33 |
| Stochastic Oscillator | 39.36 | 80.83 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).